321 related articles for article (PubMed ID: 27096289)
21. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
22. The Role of Steroids in the Management of Diabetic Macular Edema.
Zur D; Iglicki M; Loewenstein A
Ophthalmic Res; 2019; 62(4):231-236. PubMed ID: 31048580
[TBL] [Abstract][Full Text] [Related]
23. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
Cutino A; Green K; Kendall R; Moore PT; Zachary C
Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663
[TBL] [Abstract][Full Text] [Related]
25. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
26. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.
Cunha-Vaz J; Ashton P; Iezzi R; Campochiaro P; Dugel PU; Holz FG; Weber M; Danis RP; Kuppermann BD; Bailey C; Billman K; Kapik B; Kane F; Green K;
Ophthalmology; 2014 Oct; 121(10):1892-903. PubMed ID: 24935282
[TBL] [Abstract][Full Text] [Related]
27. A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND).
Figueira J; Henriques J; Amaro M; Rosas V; Alves D; Cunha-Vaz J
Ophthalmic Res; 2017; 57(3):166-172. PubMed ID: 28178701
[TBL] [Abstract][Full Text] [Related]
28. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
[TBL] [Abstract][Full Text] [Related]
29. Emerging drugs for diabetic macular edema.
Schwartz SG; Flynn HW; Scott IU
Expert Opin Emerg Drugs; 2014 Sep; 19(3):397-405. PubMed ID: 25141904
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546
[TBL] [Abstract][Full Text] [Related]
31. The Role of Anti-VEGF Therapy in the Treatment of Diabetic Macular Edema.
Moshfeghi DM; Kaiser PK; Michels S; Midena E; Kitchens JW; Prenner JL; Regillo CD; Reichel E
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6 Suppl):S4-S14. PubMed ID: 27348433
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
[TBL] [Abstract][Full Text] [Related]
35. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
[TBL] [Abstract][Full Text] [Related]
36. INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS.
Yang Y; Bailey C; Loewenstein A; Massin P
Retina; 2015 Dec; 35(12):2440-9. PubMed ID: 26352555
[TBL] [Abstract][Full Text] [Related]
37. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema.
Holden SE; Currie CJ; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):45-52. PubMed ID: 28881146
[TBL] [Abstract][Full Text] [Related]
38. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide.
Rensch F; Spandau UH; Wickenhäuser A; Jonas JB
Acta Ophthalmol; 2010 Mar; 88(2):e36-7. PubMed ID: 19210330
[No Abstract] [Full Text] [Related]
39. An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema.
Wang JK; Huang TL; Su PY; Chang PY
Eye Sci; 2015 Dec; 30(4):176-83. PubMed ID: 27215008
[TBL] [Abstract][Full Text] [Related]
40. INTRAVITREAL DEXAMETHASONE IMPLANT IN PATIENTS WITH RANIBIZUMAB PERSISTENT DIABETIC MACULAR EDEMA.
Zhioua I; Semoun O; Lalloum F; Souied EH
Retina; 2015 Jul; 35(7):1429-35. PubMed ID: 26102440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
